DEFA14A: NeuroMetrix to be Acquired by electroCore in Merger Deal

NeuroMetrix has agreed to be acquired by electroCore, with shareholders receiving cash and contingent value rights.

Summary

• NeuroMetrix has entered into a definitive merger agreement with electroCore, where electroCore will acquire NeuroMetrix.
• The transaction is expected to close late in the first quarter of 2025.
• NeuroMetrix shareholders will receive cash equivalent to the company's net cash balance at closing, estimated to be approximately $9 million, subject to adjustments.
• Shareholders will also receive one contingent value right (CVR) per share, entitling them to potential proceeds from the divestiture of the DPNCheck platform and royalties on Quell product sales up to $500,000 over two years.
• The merger is subject to shareholder approval, NeuroMetrix having at least $8 million of net cash at closing, and the filing of NeuroMetrix's Form 10-K for the fiscal year ended December 31, 2024, along with other customary closing conditions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company is being acquired, the deal provides a return of cash to shareholders and potential upside through CVRs. The language is generally optimistic about the future of Quell technology and the divestiture of DPNCheck.

Positives

• The transaction allows NeuroMetrix to efficiently return balance sheet cash to shareholders.
• Shareholders have potential upside through the contingent value rights (CVRs).
• The merger is expected to expand patient access to Quell wearable neuromodulation technology through electroCore's commercial channels.
• The DPNCheck business is expected to be divested, ensuring continued access to its diagnostic capabilities.

Negatives

• The cash payment to shareholders is subject to adjustments and deductions, which may reduce the final amount.
• The CVRs are non-tradeable and their value is contingent on future events, including the divestiture of DPNCheck and sales of Quell products.
• The transaction is subject to several conditions, including shareholder approval and a minimum net cash balance, which could delay or prevent the merger.

Risks

• The transaction may not be completed in a timely manner or at all.
• Failure to satisfy closing conditions, including shareholder approval and regulatory approvals, could prevent the merger.
• The merger agreement may be terminated under certain circumstances, potentially requiring NeuroMetrix to pay a termination fee.
• There are risks related to obtaining necessary financing to complete the merger.
• The announcement or pendency of the transaction could negatively impact NeuroMetrix's business relationships and operations.
• Management's attention may be diverted from ongoing business operations.
• Legal proceedings related to the merger agreement could arise.

Future Outlook

The document anticipates the transaction closing late in the first quarter of 2025, with potential upside for shareholders through CVRs tied to the divestiture of DPNCheck and future sales of Quell products. The company expects patients with chronic pain to have expanded access to Quell technology through electroCore's commercial channel.

Management Comments

• Shai N. Gozani, M.D., Ph.D., Chairman and CEO of NeuroMetrix, stated that the transaction represents a positive outcome for shareholders, returning balance sheet cash and providing potential upside through the CVR.
• Gozani also noted that the transaction is expected to expand patient access to Quell technology through electroCore's commercial channel.

Industry Context

This announcement reflects a trend of consolidation in the medical device and bioelectronic medicine sectors, where companies seek to leverage synergies and expand market reach through acquisitions. electroCore's acquisition of NeuroMetrix is likely aimed at broadening its product portfolio and market presence in the neuromodulation space.

Comparison to Industry Standards

• The structure of the deal, with a combination of cash and contingent value rights, is a common approach in acquisitions of companies with both established and early-stage assets.
• The estimated net cash payout of $9 million is relatively small compared to the overall market capitalization of NeuroMetrix, suggesting that the CVRs are a significant component of the deal's value.
• The contingent value rights tied to future sales and divestitures are a common mechanism to bridge valuation gaps and align the interests of the acquiring and acquired companies.
• The two-year royalty period for Quell sales is a typical timeframe for such arrangements, providing a defined period for potential upside.

Stakeholder Impact

• Shareholders will receive cash and contingent value rights.
• Patients with chronic pain are expected to have expanded access to Quell technology.
• Physicians and patients will continue to benefit from the DPNCheck platform through its divestiture.

Next Steps

• NeuroMetrix will file a proxy statement with the SEC.
• NeuroMetrix will mail the proxy statement to shareholders.
• NeuroMetrix shareholders will vote on the merger agreement.
• The transaction is expected to close late in the first quarter of 2025, subject to closing conditions.

Key Dates

Keywords

merger, acquisition, NeuroMetrix, electroCore, contingent value rights, CVR, DPNCheck, Quell, shareholders, net cash, divestiture, neuromodulation, bioelectronic medicine